Huntington's disease is a fatal neurodegenerative disorder caused by an expanded polyglutamine repeat in huntingtin (HTT) protein. We previously showed that calorie restriction ameliorated Huntington's disease pathogenesis and slowed disease progression in mice that model Huntington's disease (Huntington's disease mice) 1 . We now report that overexpression of sirtuin 1 (Sirt1), a mediator of the beneficial metabolic effects of calorie restriction, protects neurons against mutant HTT toxicity, whereas reduction of Sirt1 exacerbates mutant HTT toxicity. Overexpression of Sirt1 improves motor function, reduces brain atrophy and attenuates mutant-HTT-mediated metabolic abnormalities in Huntington's disease mice. Further mechanistic studies suggested that Sirt1 prevents the mutant-HTT-induced decline in brain-derived neurotrophic factor (BDNF) concentrations and the signaling of its receptor, TrkB, and restores dopamine-and cAMP-regulated phosphoprotein, 32 kDa (DARPP32) concentrations in the striatum. Sirt1 deacetylase activity is required for Sirt1-mediated neuroprotection in Huntington's disease cell models. Notably, we show that mutant HTT interacts with Sirt1 and inhibits Sirt1 deacetylase activity, which results in hyperacetylation of Sirt1 substrates such as forkhead box O3A (Foxo3a), thereby inhibiting its pro-survival function. Overexpression of Sirt1 counteracts the mutant-HTT-induced deacetylase deficit, enhances the deacetylation of Foxo3a and facilitates cell survival. These findings show a neuroprotective role for Sirt1 in mammalian Huntington's disease models and open new avenues for the development of neuroprotective strategies in Huntington's disease.
Alteration of cellular metabolism has a crucial role in the pathogenesis of Huntington's disease [2] [3] [4] , raising the possibility of developing therapeutic interventions in Huntington's disease that activate metabolic defenses. Sirt1 is an evolutionarily conserved protein with NAD + -dependent deacetylase activity that participates in cellular metabolism 5 . Sirt1 has neuroprotective roles in models of neurodegenerative diseases 6 . Whether Sirt1 has a protective role in mammalian Huntington's disease remains unknown, however, as results from lower organisms such as Caenorhabditis elegans 7 and Drosophila melanogaster 8 are contradictory.
To determine the role of Sirt1 in mammalian Huntington's disease models, we took advantage of a Sirt1 transgenic mouse model in which the expression of Sirt1 is driven by a prion protein promoter 9 . Mice in this model strongly overexpress Sirt1 in the brain (Fig. 1a) , although we also observed detectable concentrations of the Sirt1 transgene in peripheral tissues (Fig. 1b) . As the first step in our experiment, we crossed these Sirt1 transgenic mice with N171-82Q Huntington's disease mice that have progressive phenotypes that resemble those in humans with Huntington's disease 1, 10 . Sirt1 overexpression significantly delayed the onset and slowed the progression of motor deficits in Huntington's disease mice (Fig. 1c) without decreasing mutant HTT concentrations (Supplementary Fig. 1a ). To determine whether improved motor function correlated with the progression of the neuropathological process, we performed an in vivo structural magnetic resonance imaging (MRI) analysis 11 . We detected significant atrophy in the striatum (P < 0.05) and neocortex (P < 0.05) of N171-82Q Huntington's disease mice, which resembled the neuropathological changes seen in human Huntington's disease. Overexpression of Sirt1 significantly attenuated the magnitude of brain atrophy ( Fig. 1d-f) . These results show that increased expression of Sirt1 attenuates neurodegeneration and improves motor function in N171-82Q Huntington's disease mice.
Having shown that overexpression of Sirt1 is protective in a Huntington's disease mouse model expressing an N-terminal mutant HTT fragment (fragment HD model), we then aimed to confirm these effects of Sirt1 in a Huntington's disease mouse model expressing full-length mutant HTT (full-length HD model). BACHD mice have motor deficits and Huntington's disease-like brain pathology Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets relatively earlier than mice from other available full-length Huntington's disease models 12, 13 . Overexpression of Sirt1 significantly attenuated motor deficits (Fig. 1g,h ) without decreasing the expression of mutant HTT (Supplementary Fig. 1b ). Brain atrophy was partially ameliorated by Sirt1 overexpression (Fig. 1i,j) , suggesting that Sirt1 also attenuates neurodegeneration in BACHD mice.
We previously showed that N171-82Q Huntington's disease mice have metabolic abnormalities that are attenuated by calorie restriction 1 . Therefore, we examined whether Sirt1 could modulate metabolic alterations in Huntington's disease mice. Overexpression of Sirt1 significantly (P < 0.05) attenuated hyperglycemia ( Supplementary  Fig. 2a) , improved glucose tolerance (Supplementary Fig. 2b,c) and attenuated weight loss in N171-82Q Huntington's disease mice (Supplementary Fig. 2d ). To determine whether the attenuation of weight loss was a result of the effect of Sirt1 on food intake, energy expenditure or both, we used Oxymax metabolic cages to measure energy expenditure continuously for a week and monitored daily food intake, and we found that Sirt1 counteracted the negative effect of mutant HTT on food intake ( Supplementary Fig. 2e ) but did not affect energy expenditure (Supplementary Fig. 2f) . Notably, insulin concentrations did not differ between N171-82Q Huntington's disease mice and wild-type (WT) control mice (315.4 ± 51.5 pg ml −1 in WT mice compared to 308.9 ± 34.4 pg ml −1 in Huntington's disease mice (mean ± s.e.m.), n = 10), but Huntington's disease mice had hyperglycemia, suggesting insulin resistance in these mice. As insulin resistance constitutes a metabolic stressor that may contribute to the neurological phenotype, we next examined the role of Sirt1 on insulin concentrations. Sirt1 overexpression did not alter insulin concentrations in control mice (318.6 ± 83.7 pg ml −1 in mice overexpressing Sirt1 compared to 315.4 ± 51.5 pg ml −1 in WT mice (mean ± s.e.m.), n = 10) but did substantially reduce insulin concentrations in Huntington's disease mice (308.9 ± 34.4 pg ml −1 in Huntington's disease mice compared to 149.1 ± 6.8 pg ml −1 in Huntington's disease mice overexpressing Sirt1 (mean ± s.e.m.), n = 10). Sirt1 decreased insulin concentrations and attenuated hyperglycemia in Huntington's disease mice, indicating that Sirt1 improves insulin sensitivity in these mice. To determine whether overexpression of Sirt1 in brain, pancreas or both contributes to this effect, we examined the Sirt1 transgene expression pattern. Whereas the Sirt1 transgene is highly expressed in various brain regions (Supplementary Fig. 3a) , we detected very low expression of it in the pancreas ( Supplementary  Fig. 3b ). Although these results suggest a central action for Sirt1 in mediating metabolic rescue, the effects of Sirt1 on the pancreas cannot be completely ruled out.
Notably, Sirt1 overexpression did not extend life span in N171-82Q Huntington's disease mice (with an average life span of 152 ± 7 d in 19 Huntington's disease mice compared to 157 ± 6 d in 26 Huntington's disease mice overexpressig Sirt1 (mean ± s.e.m.)). Similar findings have been noted in other studies of mice that model Huntington's disease, in which reductions in neuropathology and improvements in motor function or normalization of glucose concentrations were observed in the absence of life span extension [14] [15] [16] [17] . In addition, Sirt1 overexpression did not alter aggregation of mutant HTT ( Supplementary Fig. 4 ), suggesting that aggregation of this mutant protein does not have a major role in the neuroprotective effects of Sirt1 in our models. Although Jeong et al. report that Sirt1 attenuates brain atrophy in R6/2 mice, suggesting a neuroprotective effect of Sirt1, they also saw increased survival and decreased aggregation of mutant HTT after overexpression of Sirt1 in R6/2 mice 18 . Notably, we showed that N171-82Q mice develop hyperglycemia and insulin resistance, which was not seen in their R6/2 model. There is a complicated relationship between insulin signaling and neurodegeneration. Whereas some reports suggest that reduced insulin signaling is protective in the central nervous system 19 , others suggest the opposite 19 . Further studies will be required to determine the relationship between insulin resistance and survival in our model. However, we emphasize that the combined data of both studies show Sirt1-mediated striatal neuroprotection indicated by reduced striatal atrophy in two different fragment models and in a full-length mouse model of Huntington's disease, strongly suggesting a neuroprotective role for Sirt1 in Huntington's disease. Next we determined the molecular basis underlying neuroprotection by Sirt1 in Huntington's disease. Huntington's disease mice are severely impaired in their ability to regulate the physiological state of striatal neurons through dopamine 20 . DARPP32 is a fundamental component of the dopamine signaling cascade 21, 22 , and Huntington's disease pathology is marked by extensive loss of medium spiny neurons that have high expression DARPP32; therefore, DARPP32 can serve as a marker of neuronal loss as well as of neuronal dysfunction in Huntington's disease 23, 24 . We observed a significant reduction of DARPP32 concentrations in both the N171-82Q and BACHD mouse models (Fig. 2a,b) , which is consistent with findings from other Huntington's disease mouse models 20 . Notably, Sirt1 restored DARPP32 concentrations in both the N171-82Q and BACHD Huntington's disease mouse models (Fig. 2a,b) , suggesting that Sirt1 may protect striatal neurons against mutant HTT by preservation of DARPP32 concentrations.
Our previous study suggests that calorie restriction increases BDNF concentrations, thereby protecting neurons from the effects of mutant HTT 1 . Reduced BDNF concentration contributes to striatal dysfunction and degeneration, and an increase in BDNF concentration is neuroprotective in Huntington's disease 25 . BDNF signaling in the brain also has a crucial role in regulating glucose metabolism 26 . BDNF is required for the normal expression of DARPP32 (ref. 27 ). BDNF concentrations were significantly decreased in our fragment Huntington's disease model mice, whereas overexpression of Sirt1 markedly restored BDNF concentrations in the fragment HD model (Fig. 2c,d ).
In addition, we found that total TrkB and phospho-TrkB concentrations were significantly decreased in a striatal cell line containing mutant HTT (Fig. 2e,f) . However, overexpression of Sirt1 maintained the concentration of phospho-TrkB but not total TrkB (Fig. 2e-g ). These experiments suggest that Sirt1-mediated restoration of BDNF concentrations and of its prosurvival signaling might be a mechanism for Sirt1 neuroprotection in Huntington's disease.
Because our data suggest that overexpression of Sirt1 has neuroprotective effects in Huntington's disease models, we next sought to determine the role of endogenous Sirt1 in mutant-HTT-induced toxicity. We showed that complete knockdown of Sirt1 led to cell death in the absence of mutant HTT (data not shown), suggesting a role for Sirt1 in neuronal survival. Partial knockdown of Sirt1 (Fig. 3a) that was not toxic at baseline led to exacerbation of mutant-HTT-induced toxicity in differentiated PC12 cells inducibly expressing a mutant N-terminal HTT fragment (Fig. 3b) . Together, these results indicate that endogenous Sirt1 has a neuroprotective role and that deficiency of Sirt1 in neurons increases the toxicity of mutant HTT.
Next, we asked whether Sirt1 deacetylase activity is required for its neuroprotection in Huntington's disease. We used a PC12 cell model in which inducible expression of mutant HTT caused cell toxicity 28 . We introduced Sirt1 expression by retroviral transduction (Fig. 3c,d) . Overexpression of Sirt1 significantly reduced mutant-HTT-induced toxicity, as indicated by a decrease in lactate dehydrogenase (LDH) release (Fig. 3e) and an increase in AlamarBlue reduction (Fig. 3f) . The deacetylase-deficient Sirt1 mutant (H363Y) 29 completely eliminated the neuroprotective effects of Sirt1 in this cellular model (Fig. 3e,f) , showing that Sirt1 deacetylase activity is required for neuroprotection.
As a deacetylase, Sirt1 is known to deacetylate and modulate the activity of key transcription factors, for example, PGC-1α (ref. 30 ), Foxo3a is highly expressed in adult brain, and recent work indicates that Foxo3a has key roles in neuronal survival under both basal and disease conditions [33] [34] [35] . We detected an interaction between Sirt1 and Foxo3a in mouse brain (Fig. 4a) . Notably, the concentrations of Foxo3a in Huntington's disease mouse brains and in striatal cells containing mutant HTT were significantly lower compared with those in wild-type control mouse brains or cells expressing normal HTT (Fig. 4b,c) . Concentrations of acetylated Foxo3a that were significantly increased in cells containing mutant HTT (Fig. 4d) returned to baseline levels with overexpression of Sirt1 (Fig. 4e) . In addition, overexpression of Sirt1 restored Foxo3a concentrations in the striatum of Huntington's disease mice (Fig. 4b) and in striatal cells containing mutant HTT (Fig. 4c) . To examine whether Foxo3a contributes to the neuroprotection by Sirt1 in Huntington's disease, we used an immortalized striatal cell model. Cells containing mutant HTT were more vulnerable to serum withdrawal compared to cells containing normal HTT, as indicated by reduced ATP concentrations ( Fig. 4f and Supplementary Fig. 5a ). Sirt1 protected cells against mutant HTT, as indicated by a recovery of ATP concentrations (Fig. 4f) . We further confirmed the neuroprotection of Sirt1 in cortical neurons transiently transfected with mutant HTT (Supplementary Fig. 6 ). Notably, reduction in the concentration of Foxo3a by RNAi knockdown compromised the protective effect of Sirt1 in striatal cells expressing full-length mutant HTT (Fig. 4g) , suggesting that expression of Foxo3a is at least in part required for Sirt1-mediated neuroprotection.
Having shown that Foxo3a partially mediates the neuroprotection by Sirt1 in the striatal cell model of Huntington's disease, we asked whether restoring Foxo3a concentrations could protect cells from mutant HTT. Although restoring Foxo3a concentrations preserved ATP (Supplementary Fig. 5b) , coexpression of Foxo3a and Sirt1 did not have an additive effect on ATP (Supplementary Fig. 5c ). Next we examined a possible link between Foxo3a concentrations and mutant HTT-induced deficits of DARPP32 and BDNF. In the striatal cell model of Huntington's disease, overexpression of Foxo3a increased the concentrations of BDNF and DARPP32, whereas knockdown of Foxo3a further decreased DARPP32 concentrations ( Supplementary  Fig. 7a-c) , suggesting that Foxo3a deficiency may contribute, either directly or indirectly, to mutant HTT-induced abnormalities in BDNF and DARPP32.
On the basis of these observations, we hypothesized that mutant HTT may influence Sirt1 deacetylase activity and thereby increase acetylation of its substrates. To examine this possibility, we first tested whether Sirt1 was able to interact with mutant HTT. Coimmunoprecipitation analyses revealed that Sirt1 interacted with mutant HTT (Fig. 4h) . We then measured Sirt1 deacetylase activity. Using a specific antibody that detects acetylated p53 at Lys382, we found increased acetylation of p53 in HEK293 T/17 cells containing mutant HTT compared to cells containing WT HTT, suggesting that the mutant HTT interfered with Sirt1 deacetylase activity (Fig. 4i) . In support of this notion, acetylated p53 was also increased in Huntington's disease mouse brains, whereas overexpression of Sirt1 led to decreased acetylation of p53 (Fig. 4j) . Together, these experiments show that mutant HTT inhibits the deacetylase activity of Sirt1 and that overexpression of Sirt1 partially corrects the hyperacetylation of Sirt1 substrates.
In conclusion, we show a neuroprotective role for Sirt1 in cell and mouse models of Huntington's disease. Using both fragment and full-length HTT transgenic mouse models, we found that Sirt1 partially prevents neurodegeneration and ameliorates metabolic abnormalities in Huntington's disease mouse models. These results are in agreement with the accompanying paper, in which Sirt1-mediated neuroprotection was observed in an R6/2 Huntington's disease mouse model 18 . From a mechanistic standpoint, our data suggest that Sirt1 may regulate the activity of multiple targets, such as Foxo3a, DARPP32, BDNF and p53, to mediate neuroprotection in Huntington's disease models. Previous work showed that BDNF induces DARPP32 expression in medium spiny striatal neurons 27 . Our data also suggest that Foxo3a regulates DARPP32 and BDNF expression. Notably, we show that Sirt1 activity is inhibited by mutant HTT and that overexpression of Sirt1 overcomes this inhibition and regulates the acetylation of its substrates. Although we examined a subset of Sirt1 substrates in our models, it is a b identified CREB regulated transcription coactivator 1 (TORC1) as a previously unknown target of Sirt1 deacetylase that regulates transcription of BDNF 18 . PGC-1α is also a substrate of Sirt1 and has been previously implicated in Huntington's disease pathogenesis [36] [37] [38] . It will be interesting to examine whether TORC1 is upstream of other Sirt1 targets, such as p53 and Foxo3a, and whether Sirt1 directly deacetylates several substrates in normal and diseased brain. Nonetheless, our data indicate that at least one of these substrates, Foxo3a, has a key role in mediating Sirt1 neuroprotection. Foxo3a has been also shown to control insulin sensitivity and influence energy metabolism 39, 40 . Thus, modulation of Foxo3a by Sirt1 may also affect alterations in energy metabolism observed in Huntington's disease models. Based on these results, we suggest that pharmacological targeting of Sirt1 to enhance its deacetylase activity may provide a new therapeutic opportunity for Huntington's disease. Small compounds with Sirt1 activation activity have been shown to be beneficial in experimental animals prone to metabolic diseases 41 , and development of Sirt1 activators with high specificity and bioavailability may also be a promising approach for the treatment of Huntington's disease.
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